Lunai Bioworks asks Nasdaq to suspend LNAI trading amid Seven Points Capital litigation

Lunai Bioworks Inc.

On October 9, 2026, Lunai Bioworks submitted a formal request to Nasdaq to immediately suspend trading of its common stock, ticker LNAI.
The request cites court-ordered discovery records in Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC, D. Del.
Submission describes substantial short selling, locate deficiencies, concentrated failures to deliver, and questions whether LNAI trading is fair and orderly.
Lunai says Nasdaq has not yet decided; the request alone does not halt trading, and Nasdaq retains authority to suspend trading.
Second Amended Complaint was filed August 26, 2026; litigation remains pending and allegations are not yet adjudicated, per the filing.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.